Who is sponsoring NCT03608462?

NCT03608462 is sponsored by Shanghai Mental Health Center.

What drugs are being tested in NCT03608462?

Interventions in NCT03608462: repetitive transcranial magnetic stimulation(DLPFC), repetitive transcranial magnetic stimulation(LPC).

What condition does NCT03608462 study?

NCT03608462 studies Schizophrenia.

Is NCT03608462 still recruiting?

NCT03608462 is currently status unknown. Last updated 27 September 2021.

Last reviewed 2021-09-27 · How we verify

NCT03608462

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Modulation of Repetitive Transcranial Magnetic Stimulation on Hippocampal Neurogenesis and Functional Network in Patients With Schizophrenia

Status unknown NA Last updated 27 September 2021

What this trial tests

NA trial testing repetitive transcranial magnetic stimulation(DLPFC) in Schizophrenia in 180 participants. Status unknown.

Timeline

1 April 2019

Primary endpoint
31 December 2020

31 December 2021

Quick facts

Lead sponsor	Shanghai Mental Health Center
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	180
Start date	1 April 2019
Primary completion	31 December 2020
Estimated completion	31 December 2021
Sites	1 location across China

Drugs / interventions tested

repetitive transcranial magnetic stimulation(DLPFC)
repetitive transcranial magnetic stimulation(LPC)

Conditions studied

Schizophrenia — all drugs for Schizophrenia →

Sponsor

Shanghai Mental Health Center — full company profile →

Who can join

Adults 18 to 50, any sex, with Schizophrenia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Based on the hypothesis that high-frequency repetitive transcranial magnetic stimulation(rTMS) on the right dorsolateral prefrontal cortex(DLPFC) and left parietal cortex(LPC) could normalise cognitive abnormalities by promoting hippocampal neurogenesis and cortical-hippocampal function in patients with schizophrenia,this research plan to utilise multimodal functional magnetic imaging method(including structural MRI,resting-state functional magnetic resonance imaging and 1H-MRS) to investigate therapeutic efficacy of intermittent theta burst stimulation (iTBS) on cognitive impairment in SZ patients with memory defects,as well as to elucidate the correlation between treatment effects and hippocampal neuroplasticity.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Emerging Pro-neurogenic Therapeutic Strategies for Neurodegenerative Diseases: A Review of Pre-clinical and Clinical Research.
Vassal M, Martins F, Monteiro B, Tambaro S, et al · · 2025 · cited 12× · PMID 38816676 · DOI 10.1007/s12035-024-04246-w
Current understanding and prospects for targeting neurogenesis in the treatment of cognitive impairment.
Liu Y, Ding X, Jia S, Gu X. · · 2026 · cited 10× · PMID 39820472 · DOI 10.4103/nrr.nrr-d-24-00802
Efficacy of Cortical-Hippocampal Target Intermittent Theta Burst Stimulation (iTBS) on Associative Memory of Schizophrenia: A Double-Blind, Randomized Sham-Controlled Trial.
Li X, Xiang Q, Cen H, Zhai Z, et al · · 2024 · cited 1× · PMID 39411184 · DOI 10.2147/ndt.s468219

Verify or expand the search:

Other recruiting trials for Schizophrenia

Currently open trials in the same condition.

NCT07424404 — A Study to Evaluate the Long-term Safety and Tolerability of KarXT and KarX-EC for the Treatment of Schizophrenia and Au · Phase 3 · recruiting
NCT07467993 — Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia · Phase 2 · recruiting
NCT07379827 — Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT) · recruiting
NCT06758414 — CBT-CP for Veterans With SMI · NA · recruiting
NCT07395206 — Acceptability, Feasibility and Preliminary Outcomes of the Kiso Mind App for Outpatients With Schizophrenia Spectrum Dis · NA · recruiting

Other Shanghai Mental Health Center trials

Trials by the same sponsor.

NCT07480408 — Neural Mechanisms of the Sensorymotor Circuit in Sensory Phenomena in OCD · NA · not yet recruiting
NCT07479771 — tTIS Targeted of the Striatum as an Intervention for MUD Patients · NA · not yet recruiting
NCT07472673 — Transcranial Temporal Interference Stimulation Targeted of the Amygdala as an Intervention for Alcohol Use Disorder Pati · NA · not yet recruiting
NCT07484750 — Efficacy and Influencing Factors of Mindfulness-Based Exposure Group Therapy for OCD · NA · recruiting
NCT07311655 — Validation of the Accuracy of an AI-Based System for Diagnosing Anxiety Disorders · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03608462 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shanghai Mental Health Center
Last refreshed: 27 September 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03608462.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing